CONTEXT: Activating mutations in the RET protooncogene have been demonstrated in multiple endocrine neoplasia 2 and sporadic medullary thyroid carcinoma (MTC). However, the complete genetic etiology underlying MTC tumorigenesis remains unclear. OBJECTIVE: Our objective was to define more precisely the chromosomal regions and uncover novel genes associated with MTC tumorigenesis. DESIGN AND SETTING: In this study, we used high resolution array-based comparative genomic hybridization to define tumor-associated copy number alterations (CNA) in 30 primary MTCs: 20 sporadic tumors (50% of which harbored RET mutation), and 10 hereditary. RESULTS: We identified 98 CNA, including 76 genomic allelic losses, two gains, and 20 copy number variations associated with MTC. Across sporadic and hereditary groups, there was a similar and overlapping pattern of predominant allelic loss. There were 29 regions containing at least 30% CNA in the 30 tumor samples. The most frequent allelic loss occurred in four loci, 7q36.1, 12p13.31, 13q12.11, and 19p13.3-11. No regions were found to be uniquely altered in the hereditary tumors. There were 21 CNA specific to sporadic MTC, with loss of 11q23.3 uniquely altered in RET negative tumors. Pathway analysis found cellular growth and proliferation as the most significant overall target, and cell death as the most significant pathway targeted in sporadic MTC. CONCLUSIONS: Our findings underscore the importance of candidate tumor suppressor genes together with RET alterations in MTCs. Despite of RET status, all MTC might share similar oncogenetic mechanisms. Dysfunction of cell proliferation and cell death may both be involved in MTC tumorigenesis.
CONTEXT: Activating mutations in the RET protooncogene have been demonstrated in multiple endocrine neoplasia 2 and sporadic medullary thyroid carcinoma (MTC). However, the complete genetic etiology underlying MTC tumorigenesis remains unclear. OBJECTIVE: Our objective was to define more precisely the chromosomal regions and uncover novel genes associated with MTC tumorigenesis. DESIGN AND SETTING: In this study, we used high resolution array-based comparative genomic hybridization to define tumor-associated copy number alterations (CNA) in 30 primary MTCs: 20 sporadic tumors (50% of which harbored RET mutation), and 10 hereditary. RESULTS: We identified 98 CNA, including 76 genomic allelic losses, two gains, and 20 copy number variations associated with MTC. Across sporadic and hereditary groups, there was a similar and overlapping pattern of predominant allelic loss. There were 29 regions containing at least 30% CNA in the 30 tumor samples. The most frequent allelic loss occurred in four loci, 7q36.1, 12p13.31, 13q12.11, and 19p13.3-11. No regions were found to be uniquely altered in the hereditary tumors. There were 21 CNA specific to sporadic MTC, with loss of 11q23.3 uniquely altered in RET negative tumors. Pathway analysis found cellular growth and proliferation as the most significant overall target, and cell death as the most significant pathway targeted in sporadic MTC. CONCLUSIONS: Our findings underscore the importance of candidate tumor suppressor genes together with RET alterations in MTCs. Despite of RET status, all MTC might share similar oncogenetic mechanisms. Dysfunction of cell proliferation and cell death may both be involved in MTC tumorigenesis.
Authors: S C Huang; C A Koch; A O Vortmeyer; S D Pack; U D Lichtenauer; P Mannan; I A Lubensky; G P Chrousos; R F Gagel; K Pacak; Z Zhuang Journal: Cancer Res Date: 2000-11-15 Impact factor: 12.701
Authors: C Guo; P S White; M J Weiss; M D Hogarty; P M Thompson; D O Stram; R Gerbing; K K Matthay; R C Seeger; G M Brodeur; J M Maris Journal: Oncogene Date: 1999-09-02 Impact factor: 9.867
Authors: Wendy van Veelen; Carola J R van Gasteren; Dennis S Acton; David S Franklin; Ruud Berger; Cornelis J M Lips; Jo W M Höppener Journal: Cancer Res Date: 2008-03-01 Impact factor: 12.701
Authors: Maha El Naofal; Adriel Kim; Hui Yi Yon; Mohamed Baity; Zhao Ming; Jacquelin Bui-Griffith; Zhenya Tang; Melissa Robinson; Elizabeth G Grubbs; Gilbert J Cote; Peter Hu Journal: Ann Clin Lab Sci Date: 2017-09 Impact factor: 1.256
Authors: Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote Journal: Thyroid Date: 2016-10-18 Impact factor: 6.568
Authors: Rozita Bagheri-Yarmand; Michelle D Williams; Elizabeth G Grubbs; Robert F Gagel Journal: J Clin Endocrinol Metab Date: 2017-03-01 Impact factor: 5.958
Authors: Karine Pozo; Emely Castro-Rivera; Chunfeng Tan; Florian Plattner; Gert Schwach; Veronika Siegl; Douglas Meyer; Ailan Guo; Justin Gundara; Gabriel Mettlach; Edmond Richer; Jonathan A Guevara; Li Ning; Anjali Gupta; Guiyang Hao; Li-Huei Tsai; Xiankai Sun; Pietro Antich; Stanley Sidhu; Bruce G Robinson; Herbert Chen; Fiemu E Nwariaku; Roswitha Pfragner; James A Richardson; James A Bibb Journal: Cancer Cell Date: 2013-10-14 Impact factor: 31.743
Authors: Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166
Authors: Ira L Kraft; Srivandana Akshintala; John W Glod; Jack F Shern; Brigitte C Widemann; Yuelin Zhu; Haiyan Lei; Claudia Derse-Anthony; Eva Dombi; Seth M Steinberg; Maya Lodish; Steven G Waguespack; Oxana Kapustina; Elizabeth Fox; Frank M Balis; Maria J Merino; Paul S Meltzer Journal: Clin Cancer Res Date: 2017-11-29 Impact factor: 12.531